JJC8-016

JJC8-016
Clinical data
Drug classAtypical dopamine reuptake inhibitor
Identifiers
  • N-[2-[bis(4-fluorophenyl)methylsulfanyl]ethyl]-3-phenylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC24H25F2NS
Molar mass397.53 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)CCCNCCSC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
  • InChI=1S/C24H25F2NS/c25-22-12-8-20(9-13-22)24(21-10-14-23(26)15-11-21)28-18-17-27-16-4-7-19-5-2-1-3-6-19/h1-3,5-6,8-15,24,27H,4,7,16-18H2
  • Key:IWZNOFWARONDLD-UHFFFAOYSA-N

JJC8-016 is an atypical dopamine reuptake inhibitor (DRI) that was derived from modafinil.[1][2][3][4] It was an early lead in the development of novel modafinil analogues with improved properties for potential use in the treatment of psychostimulant use disorder (PSUD).[1][3]

  1. ^ a b Tanda G, Hersey M, Hempel B, Xi ZX, Newman AH (February 2021). "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder". Curr Opin Pharmacol. 56: 13–21. doi:10.1016/j.coph.2020.07.007. PMC 8247144. PMID 32927246.
  2. ^ Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX (January 2021). "New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders". Annu Rev Pharmacol Toxicol. 61 (1): 609–628. doi:10.1146/annurev-pharmtox-030220-124205. PMC 9341034. PMID 33411583.
  3. ^ a b Hersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, et al. (2021). "Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?". Front Neurosci. 15: 656475. doi:10.3389/fnins.2021.656475. PMC 8187604. PMID 34121988.
  4. ^ Zhang HY, Bi GH, Yang HJ, He Y, Xue G, Cao J, et al. (August 2017). "The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic". Neuropsychopharmacology. 42 (9): 1871–1883. doi:10.1038/npp.2017.41. PMC 5564383. PMID 28266501.